With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

Patients on the drug, also known as KarXT, achieved a 16.9-point reduction on the scale, Zai Lab said. The improvement for those on placebo came to 7.7 points. Zai Lab’s phase 3 trial looked at ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

KarXT demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo (p=0.0014) Trial also met all secondary endpoints, demonstrating ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT ...

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a statistically significant 9.2-point reduction in the Positive and ...